European Organisation for Research and Treatment of Cancer

So the authors for this study, this is a separate publication but same study, used three questionnaires to assess patient-reported outcomes.

The EORTC Quality of Life Questionnaire C30, the QLQ Ovarian Cancer Module 28, and the Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index, or FOSI.

Now, the baseline questionnaires were available for almost all patients, 89 for the OV28 and the FOSI, and 94 for the C30.

The OV28 demonstrated significantly higher improvements in abdominal and GI symptoms, which you can see here, at week 8 and 9, with a difference of about 12.7%, and this was statistically significant, and this persisted to week 16 to 18.